Obermatt
See Similar Stocks →

Kiniksa Pharmaceuticals

NSQ:KNSA · GB00BRXB0C07
BiotechnologyMedium

360

99
EV / EBIT73
Price / Owner Earnings3
Owner Earnings Yield82
Dividend Yield1
Price/Sales28
EV / Gross Profit62
Price/Book28
Return on Capital90
Cash Return on Capital86
Return on Equity86
EBIT Margin73
Gross Profitability83
Accruals41
Owner Earnings Margin76
Sales growth80
Profit Growth74
Long-Term EPS Growth90
Reinvestment17
Price momentum83
Debt load95
Refinancing34
Debt Payback100
Liquidity—
Analyst ratings67
Opinion Changes50
Price Target Upside23
Market mood73
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Kiniksa Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUK
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2015
Websitekiniksa.com
ISINGB00BRXB0C07
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyChronic DiseasesCardiovascularInflammationDermatologyBiopharmaBiotechnology

Description

Kiniksa Pharmaceuticals International, plc operates as a biopharmaceutical company. The company is developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. The company’s portfolio of ass…

Analysis

Quality compounder

Kiniksa Pharmaceuticals International, plc earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is expensive. The owner-earnings multiple stands at 54.1×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 20% a year, against analyst forecasts of 39%. The price, in other words, assumes less than the experts do.

Growth is solid; the safety picture is sturdy. The company scores 20/20 on our value-creation score: strong value creator. Analysts lean positive.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

Similar Stocks

The companies this stock is ranked against.

Compare Kiniksa Pharmaceuticals with its peers
NewAmsterdam Pharma Company
NMQ:NAMS
16
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Pharming
AEX:PHARM
77
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mincon Group
ISE:MIO
89
CountryIreland
IndustryMachinery
SizeSmall
Full Stock Analysis →
NovoCure
NSQ:NVCR
42
CountryJersey
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
SHL Telemedicine
SWX:SHLTN
24
CountryIsrael
IndustryHealth Care Providers & Services
SizeX-Small
Full Stock Analysis →
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →